Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(SAU: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
All news about
 
Pharma’s Huge Threat (and Opportunity): mRx
June 23, 2012
It was only a matter of time before healthcare providers would start prescribing mHealth apps as soon as they proved to be as or more effective than prescription drugs. Happtique, a mobile health... Read More
category mHealth , patient relationship management , Health , and 19 more.
from TechCrunch
Index Launches Its First Life Sciences Fund: $200M And Partnering With Glaxo and Johnson & Johnson
March 21, 2012
Index Ventures may be best known on these pages for its technology investments, but today it launched a new fund that points to how the company is willing to put its money into other examples of strong... Read More
category TC , Life Sciences , Venture Capital , and 3 more.
from TechCrunch
Dumb Employers, Lucky Startups And An Untapped Reservoir
March 19, 2012
A group of women is re-entering the workforce today and reshaping how products are made across key tech sectors like health & wellness, commerce and social products. Not only do they have the... Read More
category Microsoft , Brad Feld , Group Health , and 21 more.
from TechCrunch
What Pharma Can Learn From the Railroads and IBM
February 26, 2012
Pharmaceutical companies are in trouble with ongoing patent cliffs with a clear choice facing them. They can follow the path of the railroad industry which is the path most are on right now.... Read More
category Data General , DEC , Health , and 16 more.
from TechCrunch
Bristol-Myers Squibb asked to cure high drug costs…
March 22, 2011
It’s still high season for proxies, which means we’re spending a lot of time wading through pages filled with discussions about executive compensation, board members’ qualifications to serve, the... Read More
category proxy , Shareholder proposals , pharmaceutical
from footnoted*
Pfizer Shrinks Its Drug Pipeline Amid R&D Cuts
March 01, 2011
In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world's largest pharmaceutical company announced large research... Read More
category Lipitor , research , pharmaceutical , and 24 more.
from DailyFinance.com
Five High Profile Health Care Companies Valuations with Warnings
February 27, 2011
The selection of top five drug / pharmaceutical companies are based on the following supportive data. It includes their short and longer-term price, and earnings projected price performance. Other than... Read More
category Short , Cycle Analysis and Inflection Points , Financial economics , and 24 more.
from CEOWORLD Magazine
The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up
February 09, 2011
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials than... Read More
category drug approval , GSK , cancer drugs , and 15 more.
from DailyFinance.com
APEIRON ACQUIRES RIGHTS FOR A PHASE II BIOLOGIC AGAINST NEUROBLASTOMA AND OTHER CANCERS FROM MERCK KGAA, GERMANY
February 01, 2011
Vienna-based biotech company Apeiron Biologics AG strengthens its cancer immunotherapy portfolio by acquiring rights to further develop and commercialize the immunocytokine hu14.18-IL2 from Merck KGaA,... Read More
category then lead product , Pharmacology , melanoma , and 32 more.
from CEOWORLD Magazine
2010 Was a Rough Year for Pharmaceutical Jobs; Will 2011 Be Better?
January 07, 2011
If you don't count the U.S. government and nonprofits, the pharmaceutical industry had the most job cuts last year. Mergers, acquisitions and major restructurings made pharma a much smaller and leaner... Read More
category big pharma , pharmaceutical stocks , MRK, PFE , and 13 more.
from DailyFinance.com
AstraZeneca's Brilinta Fails to Win FDA Approval
December 17, 2010
AstraZeneca failed to win FDA approval for its heart drug Brilinta, which the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster.... Read More
category AZN , heart medications , pharmaceutical industry , and 13 more.
from DailyFinance.com
WikiLeaks: Did Pfizer Use Unethical Tactics to Evade a Clinical Trial Settlement?
December 10, 2010
According to the latest leaked U.S. diplomatic cables from WikiLeaks, Pfizer hired investigators to try to uncover evidence of corruption in order to pressure the Nigerian attorney general to drop the... Read More
category corruption , pfizer nigeria , nigerian , and 20 more.
from DailyFinance.com
Johnson & Johnson Launches Offer for Crucell
December 08, 2010
Johnson & Johnson has finally launched its bid for Dutch vaccine-maker Crucell -- as part of efforts to expand into the biotech market Continue reading Johnson & Johnson Launches Offer for Crucell... Read More
category JohnsonAndJohnsonjnj , pharmaceutical stocks , Johnson and Johnson JNJ , and 18 more.
from DailyFinance.com
FDA Panel Backs Orexigen's Diet Pill
December 07, 2010
After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics's Contrave. If the FDA... Read More
category food and drug administration , pharmaceutical , OREX , and 18 more.
from DailyFinance.com
Vision China- GlaxoSmithKline to buy Nanjing MeiRui Pharma Co. for $70m
December 07, 2010
GlaxoSmithKline PLC (GSK), anglo-American drugs giant, has entered into an agreement to acquire Chinese urology and allergy treatments specialist Nanjing MeiRui Pharma Co., Ltd for around $70 million.... Read More
category treatment for benign prostatic hyperplasia , overactive bladder syndrome , pharmaceutical , and 33 more.
from CEOWORLD Magazine
Finally Japan’s Otsuka Holdings Sets Price for $2.4 Billion largest health-care Tokyo IPO
December 06, 2010
Japan’s Otsuka Holdings priced shares in its $2.4 billion initial public offering (IPO), 2nd-biggest Japan IPO this year after Dai-ichi Life, at the lower end of its range, reflecting investors’... Read More
category Otsuka Holdings IPO , Otsuka Holdings , Financial economics , and 27 more.
from CEOWORLD Magazine
Genzyme considering contingent value right (CVR) deal structure to help deadlock with Sanofi-Aventis
November 21, 2010
Genzyme Corp. (GENZ), U.S. biotechnology firm, is exploring a new deal structure that might help break $18.5 billion hostile takeover bid deadlock with French drugmaker Sanofi-Aventis SA (SASY), as it... Read More
category Genzyme Corp/ , Sanofi/Aventis , Oklahoma City , and 21 more.
from CEOWORLD Magazine
Eisai Co Ltd’s breast cancer drug Halaven (eribulin mesylate) approved by U.S. Food and Drug Administration
November 15, 2010
Eisai Co Ltd’s (4523.TO, ESALY) new breast cancer drug, Halaven (eribulin mesylate), has been approved as a treatment for metastatic breast-cancer patients who have received at least two prior... Read More
category National Cancer Institute , metastatic breast cancer , Ixabepilone , and 28 more.
from CEOWORLD Magazine
Spanish Grifols improves Talecris Biotherapeutics Holdings Corp bid
November 11, 2010
Spanish pharmaceutical firm Grifols SA (GRLS.MC), Europe’s largest maker of blood-plasma products, has bowed to a class-action suit filed by some shareholders of its bid target Triangle-based Talecris... Read More
category Europe , blood/plasma products , Grifols , and 17 more.
from CEOWORLD Magazine
Novartis Halts Lung Cancer Drug Study
November 11, 2010
Novartis will discontinue studies of an experimental lung-cancer cancer drug because of disappointing trial results. Continue reading Novartis Halts Lung Cancer Drug Study Novartis Halts Lung Cancer... Read More
category NVS , generics , cancer , and 2 more.
from DailyFinance.com
Sanofi-Aventis to Cut 1,700 Jobs in the U.S.
October 08, 2010
Sanofi-Aventis ( SNY ) said Friday it plans to lay off 1,700 workers at its U.S. pharmaceutical operations, which amounts to about 25% of its U.S. workforce. The cutbacks are part of an ongoing... Read More
category layoffs , pharmaceutical industry , Sanofi/Aventis , and 7 more.
from DailyFinance.com
Sanofi Aventis CEO Chris Viehbacher Insists Genzyme Deal at a reasonable price
September 15, 2010
French drugmaker Sanofi Aventis SA (SASY), world’s fourth-biggest pharmaceutical company, Chief Executive Officer Chris Viehbacher sees a reasonable chance of buying Genzyme (GENZ) at a fair price, but... Read More
category Pharmacology , USD , pharmaceutical , and 31 more.
from CEOWORLD Magazine
Legal Briefing: IRS and Justice Department Target More Rich Tax Cheats
July 07, 2010
Now that they are nearly done squeezing Swiss bank UBS for information about its wealthy tax-dodging clients, the IRS and the Justice Department are moving on to new tax fraud targets: Clients of... Read More
category Supreme Court , second amendment , merck , and 21 more.
from DailyFinance.com
InterMune Shares Soar After FDA Panel Backs Lung Disease Drug
March 09, 2010
InterMune shares soared over 60% after hours after it came closer to FDA approval of its experimental treatment for a fatal lung disease. An advisory panel voted to approve the drug despite... Read More
category drug approval , FDA , itmn , and 1 more.
from DailyFinance.com
Why American Industry Could Become Dangerous
February 23, 2010
In January 2010, the Supreme Court gave corporations unlimited power to spend money on political campaigns, effectively swaying politicians in their favor. But by doing this, Washington could become... Read More
category government , banking , TM , and 3 more.
from DailyFinance.com
Johnson and Johnson – Valuation Compression has Created a Good Entry Point
February 23, 2010
Johnson & Johnson (JNJ, news: 63.49 -0.32 -0.50%, cap: 175.2B, 1yr target: 71.18) is likely the world’s largest and most diverse health-care company. They operate c three divisions: Pharmaceutical,... Read More
category johnson and johnson , JNJ , Consumer , and 8 more.
from CEOWORLD Magazine
Genzyme's bad year gets worse: Experimental kidney drug a no-go
November 18, 2009
DailyFinance : For Genzyme Corp (GENZ), this year seems to have been plagued with one piece of bad news after another. On Wednesday, the biotechnology company announced that it was dropping development... Read More
category food and drug administration , pharmaceutical , kidney , and 16 more.
from DailyFinance.com
Amgen's troubles keep compounding; Aranesp studies reveal greater risks
November 11, 2009
DailyFinance : It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen (AMGN) just can't catch a break, nor for that matter, create one. Recently, Amgen was hit with a double whammy... Read More
category bmy , aranesp , amgen , and 29 more.
from DailyFinance.com
German drug and chemical maker Merck KGaA net income falls
October 26, 2009
var fbShare = {url: 'http://ceoworld.biz/ceo/2009/10/26/german-drug-and-chemical-maker-merck-kgaa-net-income-falls/',size:'large'}German pharmaceutical and chemical company Merck KGaA (MRCG.DE) said... Read More
category Tech and Web , Sharp Corp , Merck , and 7 more.
from CEOWORLD Magazine
Ranbaxy Laboratories a unit of Japan’s Daiichi Sankyo Posts Profit, cost efficiency a reason CEO Atul Sobti says
October 26, 2009
var fbShare = {url: 'http://ceoworld.biz/ceo/2009/10/26/ranbaxy-laboratories-a-unit-of-japans-daiichi-sankyo-posts-profit-cost-efficiency-a-reason-ceo-atul-sobti-says/',size:'large'}Ranbaxy... Read More
category Tech and Web , Ranbaxy , Ranbaxy Laboratories , and 2 more.
from CEOWORLD Magazine
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here